May 9, 2023 -- Adaptive Biotechnologies on Tuesday announced that the U.S. Food and Drug Administration (FDA) has accepted an investigational new drug (IND) application submitted by its collaborator, Genentech, for a neoantigen-directed T-cell receptor (TCR)-based T-cell therapy.
This IND is the first TCR-based therapy drug candidate to advance to clinical development from Adaptive Biotechnologies' oncology collaboration with Genentech, a member of the Roche Group.
Under the terms of the collaboration agreement signed in 2019, Genentech has responsibility for clinical, regulatory, and commercialization efforts for any T-cell therapy product candidate.
The collaboration utilizes Genentech's cancer immunotherapy research and development expertise and Adaptive's proprietary T-cell receptor (TCR) discovery platform, with the aim of developing tailored cellular therapy for each patient's individual cancer, the firms said.
Copyright © 2023 scienceboard.net